Revelation Biosciences, Inc. (REVB)
Nasdaq: REVB · Pharmaceutical Preparations · San Diego, CA · filing with the SEC since 2020
Income statement, as filed
In US dollars (USD), as filed; per-share figures in US dollars; share counts. The fiscal year ends in December.| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|
| Period ending | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 |
| Report filed | Feb 26, 2026 | Mar 6, 2025 | Mar 22, 2024 | Mar 30, 2023 | Apr 15, 2022 | Mar 31, 2021 | · |
| Research and development | 4,063,857 | 3,548,996 | 4,145,902 | 5,377,400 | 6,914,756 | · | · |
| General and administrative | 5,006,957 | 4,426,113 | 4,510,762 | 5,487,111 | 5,035,729r | 145,492 | · |
| Total operating expenses | 9,070,814 | 7,975,109 | 8,656,664 | 10,864,511 | 11,950,485r | 145,492 | · |
| Operating income | -9,070,814 | -7,975,109 | -8,656,664 | -10,864,511 | -11,950,485 | · | · |
| Interest expense | · | · | · | · | 41,759 | · | · |
| Interest and investment income | · | · | · | · | 222 | 9,325 | · |
| Other income (expense), net | 155,007 | -7,144,868 | 207,473 | 34,962 | -36,352r | -1,485,008r | · |
| Total non-operating income (expense) | 157,165 | -7,063,427 | 8,536,410 | 34,962 | -36,352 | · | · |
| Income before income taxes | · | · | · | · | · | -1,630,500r | · |
| Income tax expense | 0 | 0 | 0 | 0 | 0 | · | · |
| Net income including non-controlling interests | · | · | · | · | -2,130,625 | -1,630,500r | · |
| Net income | -8,913,649 | -15,038,536 | -120,254 | -10,829,549 | -11,986,837r | -1,630,500r | -3,638 |
| Net income to common shareholders | -14,865,177 | -15,038,536 | · | · | 6,896 | · | · |
| Earnings per share, basic | -23.95 | -1,052.16r | -101.28rb | -28,646.40rb | -60,579.0646rb | -969.265b | · |
| Earnings per share, diluted | -23.95 | -1,052.16r | -101.28rb | -28,646.40rb | -60,579.0646b | · | · |
| Earnings per share, basic and diluted | · | · | · | · | · | -969.265rb | · |
| Weighted average shares, basic | 620,785 | 14,293r | 1,187rb | 378rb | 198rb | 1,691b | · |
| Weighted average shares, diluted | 620,785 | 14,293r | 1,187rb | 378rb | 198b | · | · |
| Weighted average shares, basic and diluted | · | · | · | · | · | 1,691rb | · |
As filed with the SEC, each figure from the newest report that carries it, and linked to it. Nothing here is computed.Share counts and per-share figures are on the newest report's basis, after the 1-for-12 reverse split.A dot is a line not tagged for that period. r restated by the company in a later report; b a share figure put on the newest basis or filed in the wrong unit. Hover a figure for its filing and note.
What each line is, and the XBRL concept behind it
Research and development spent on inventing what it sells next
us-gaap:ResearchAndDevelopmentExpenseGeneral and administrative the cost of running the company itself
us-gaap:GeneralAndAdministrativeExpenseTotal operating expenses the running costs together
us-gaap:OperatingExpensesOperating income profit from running the business, before interest and tax
us-gaap:OperatingIncomeLossInterest expense what its borrowing cost
us-gaap:InterestExpenseInterest and investment income what its cash and investments earned
us-gaap:InvestmentIncomeInterestOther income (expense), net gains and costs outside the business
us-gaap:OtherNonoperatingIncomeExpenseTotal non-operating income (expense) everything outside the business, together
us-gaap:NonoperatingIncomeExpenseIncome before income taxes profit before tax
us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterestIncome tax expense tax charged on the period's profit
us-gaap:IncomeTaxExpenseBenefitNet income including non-controlling interests the whole group's profit, minority holders' share included
us-gaap:ProfitLossNet income the profit or loss that belongs to the company's shareholders
us-gaap:NetIncomeLossNet income to common shareholders what is left for common shareholders
us-gaap:NetIncomeLossAvailableToCommonStockholdersBasicEarnings per share, basic net income per share outstanding
us-gaap:EarningsPerShareBasicEarnings per share, diluted net income per share, counting every share that could be issued
us-gaap:EarningsPerShareDilutedEarnings per share, basic and diluted net income per share, where both counts are the same
us-gaap:EarningsPerShareBasicAndDilutedWeighted average shares, basic the average count of shares outstanding
us-gaap:WeightedAverageNumberOfSharesOutstandingBasicWeighted average shares, diluted the average count with every share that could be issued
us-gaap:WeightedAverageNumberOfDilutedSharesOutstandingWeighted average shares, basic and diluted the average count, where both counts are the same
us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted